Suppr超能文献

补体在肿瘤生长中的作用。

The role of complement in tumor growth.

机构信息

Oncology Division (CIMA), and Department of Biochemistry and Genetics (School of Science), University of Navarra, Pamplona, Spain,

出版信息

Adv Exp Med Biol. 2014;772:229-62. doi: 10.1007/978-1-4614-5915-6_11.

Abstract

Complement is a central part of the immune system that has developed as a first defense against non-self cells. Neoplastic transformation is accompanied by an increased capacity of the malignant cells to activate complement. In fact, clinical data demonstrate complement activation in cancer patients. On the basis of the use of protective mechanisms by malignant cells, complement activation has traditionally been considered part of the body's immunosurveillance against cancer. Inhibitory mechanisms of complement activation allow cancer cells to escape from complement-mediated elimination and hamper the clinical efficacy of monoclonal antibody-based cancer immunotherapies. To overcome this limitation, many strategies have been developed with the goal of improving complement-mediated effector mechanisms. However, significant work in recent years has identified new and surprising roles for complement activation within the tumor microenvironment. Recent reports suggest that complement elements can promote tumor growth in the context of chronic inflammation. This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer.

摘要

补体是免疫系统的核心部分,它作为针对非自身细胞的第一道防线而发展。肿瘤转化伴随着恶性细胞激活补体的能力增强。事实上,临床数据表明癌症患者存在补体激活。基于恶性细胞对保护机制的利用,补体激活传统上被认为是机体对癌症免疫监视的一部分。补体激活的抑制机制使癌细胞能够逃避补体介导的消除,并阻碍基于单克隆抗体的癌症免疫疗法的临床疗效。为了克服这一限制,已经开发了许多策略,旨在改善补体介导的效应机制。然而,近年来的大量工作确定了补体激活在肿瘤微环境中的新的、令人惊讶的作用。最近的报告表明,补体成分可以在慢性炎症的情况下促进肿瘤生长。本章综述了描述补体激活在癌症免疫中的作用的数据,这些数据提供了可能有助于开发更有效的控制癌症的治疗方法的见解。

相似文献

1
The role of complement in tumor growth.
Adv Exp Med Biol. 2014;772:229-62. doi: 10.1007/978-1-4614-5915-6_11.
2
Complement as a Biological Tool to Control Tumor Growth.
Front Immunol. 2018 Sep 25;9:2203. doi: 10.3389/fimmu.2018.02203. eCollection 2018.
3
Cancer and the complement cascade.
Mol Cancer Res. 2010 Nov;8(11):1453-65. doi: 10.1158/1541-7786.MCR-10-0225. Epub 2010 Sep 24.
4
Complement and cancer: activation of the alternative pathway as a theoretical base for immunotherapy.
Adv Immun Cancer Ther. 1985;1:125-66. doi: 10.1007/978-1-4612-5068-5_4.
5
Complement in monoclonal antibody therapy of cancer.
Immunol Res. 2014 Aug;59(1-3):203-10. doi: 10.1007/s12026-014-8542-z.
6
Myelinated dorsal root ganglion cultures activate both the alternative and classical pathways of complement.
J Neurol Sci. 1999 Jun 1;165(2):160-9. doi: 10.1016/s0022-510x(99)00104-5.
7
Physiology and pathophysiology of complement: progress and trends.
Crit Rev Clin Lab Sci. 1995;32(3):265-98. doi: 10.3109/10408369509084686.
8
The role of the complement system in cancer.
J Clin Invest. 2017 Mar 1;127(3):780-789. doi: 10.1172/JCI90962.
9
Complement inhibition in cancer therapy.
Semin Immunol. 2013 Feb;25(1):54-64. doi: 10.1016/j.smim.2013.04.001. Epub 2013 May 24.
10
The complement system as a target in cancer immunotherapy.
Eur J Immunol. 2024 Oct;54(10):e2350820. doi: 10.1002/eji.202350820. Epub 2024 Jul 12.

引用本文的文献

3
The complement system and kidney cancer: pathogenesis to clinical applications.
J Clin Invest. 2025 May 1;135(9). doi: 10.1172/JCI188351.
4
The role of the tumor microenvironment in HNSCC resistance and targeted therapy.
Front Immunol. 2025 Apr 1;16:1554835. doi: 10.3389/fimmu.2025.1554835. eCollection 2025.
5
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.
Cancers (Basel). 2025 Feb 27;17(5):832. doi: 10.3390/cancers17050832.
6
C5aR1 Promotes Invasion, Metastasis, and Poor Prognosis in Cutaneous Squamous Cell Carcinoma.
Am J Pathol. 2025 Jun;195(6):1158-1171. doi: 10.1016/j.ajpath.2025.02.004. Epub 2025 Mar 6.
7
Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancer.
bioRxiv. 2025 Feb 12:2025.02.10.637503. doi: 10.1101/2025.02.10.637503.
8
The role of the C5a-C5aR pathway in iron metabolism and gastric cancer progression.
Front Immunol. 2025 Jan 9;15:1522181. doi: 10.3389/fimmu.2024.1522181. eCollection 2024.
9
Three-dimensional genome architecture in intrahepatic cholangiocarcinoma.
Cell Oncol (Dordr). 2025 Jan 20. doi: 10.1007/s13402-024-01033-6.
10
Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells.
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2405824121. doi: 10.1073/pnas.2405824121. Epub 2024 Dec 18.

本文引用的文献

1
Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.
Immunol Res. 2013 May;56(1):109-21. doi: 10.1007/s12026-012-8381-8.
2
Tumor microenvironment and myeloid-derived suppressor cells.
Cancer Microenviron. 2013 Aug;6(2):169-77. doi: 10.1007/s12307-012-0126-7. Epub 2012 Dec 16.
5
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.
J Immunol. 2012 Nov 1;189(9):4674-83. doi: 10.4049/jimmunol.1201654. Epub 2012 Oct 1.
6
Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.
J Immunol. 2012 Sep 15;189(6):2985-94. doi: 10.4049/jimmunol.1200846. Epub 2012 Aug 22.
7
Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids.
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13757-62. doi: 10.1073/pnas.1121309109. Epub 2012 Aug 8.
8
Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.
Clin Exp Immunol. 2012 Aug;169(2):100-8. doi: 10.1111/j.1365-2249.2012.04596.x.
9
Altered expression of sialidases in human cancer.
Adv Exp Med Biol. 2012;749:257-67. doi: 10.1007/978-1-4614-3381-1_17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验